On June 7, Chiatai Tianqing Pharmaceutical Group and China Resources Pharmaceutical Commercial signed a strategic cooperation agreement in Tianjin. Based on the principle of resource sharing, complementary advantages and common development, the two parties will carry out in-depth cooperation in the fields of pharmaceutical research and development, production, sales and circulation, and jointly help the sustainable development of China's pharmaceutical industry. Chiatai Tianqing's commercial director Qi Tianze and CR Pharmaceuticals Commercial Deputy General Manager Dong Hao signed the agreement on behalf of the two parties.

As one of the leading pharmaceutical companies in China, Chiatai Tianqing has always been committed to researching and developing innovative drugs, improving drug quality and meeting patients' needs. With strong R&D strength and market competitiveness, the company has won wide recognition and trust. As an important pillar industry of China Resources Group, China Resources Pharmaceutical Commercial has a comprehensive pharmaceutical distribution network and market channels, and is one of the most powerful pharmaceutical commercial enterprises in China.

According to the agreement, the two parties will cooperate in the following aspects: first, strengthening sales channel expansion, jointly developing domestic and international markets, and improving accessibility of medicines; second, strengthening brand promotion, and enhancing the influence of the two brands; and third, strengthening digital transformation, and utilizing modern technology to improve operational efficiency and customer service level.

The signing of this strategic cooperation marks a new stage in the cooperation between Chiatai Tianqing and CR Pharmaceutical Commercial in the pharmaceutical industry. Both parties will give full play to their respective advantages, realize resource sharing and complement each other's strengths, and jointly promote the innovative development of the pharmaceutical industry. Especially in digital transformation, which has now become an important trend in the cooperation between pharmaceutical companies and distribution companies, the two sides will introduce technologies such as Internet of Things, big data, cloud computing and explore the joint construction of a regional-type service center. This is not only conducive to improving overall competitiveness, but will also bring more choices of high-quality medicines to the majority of patients.

In the future, Chiatai Tianqing and CR Pharmaceuticals Commercial will continue to deepen their cooperation and work hand in hand to contribute to the building of a human health and wellness community. At the same time, both parties also look forward to working with more excellent pharmaceutical enterprises to jointly promote the prosperous development of China's pharmaceutical industry.

https://mp.weixin.qq.com/s?__biz=MzA5NDE4ODc2MA==&mid=2650367458&idx=1&sn=fafda9392c9a9927f42126a868077fdb&chksm=885fa055bf2829433c86fd9def39c779993c45876e398eea4eaedf2539efa3a7402790f651f2&mpshare=1&scene=1&srcid=06137WpXFlVRBMBCjQcZAd5B&sharer_shareinfo=5e6c15aee9e6e0856f8bbd51527604ba&sharer_shareinfo_first=5e6c15aee9e6e0856f8bbd51527604ba#rd